Coquí RadioPharmaceuticals Corp. is working to become the first commercial producer of lifesaving medical isotopes in the United States.  In 2012, Congress passed legislation making it a national priority to produce Molybdenum-99, an isotope necessary to detect a wide range of diseases, including cardiovascular disease and cancer.

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic Inc. announces CE mark and international launch of the Resolute Onyx Drug-Eluting Stent (DES). The first live patient implant of the Resolute Onyx DES occurred recently during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain. The Resolute Onyx Drug-Eluting Stent is not approved in the United States.

St. Mary’s Health Care System installed two Vantage Titan 1.5T MR (magnetic resonance) systems from Toshiba America Medical Systems Inc. St. Mary’s utilizes the systems to enhance its cardiac imaging program and for advanced imaging studies that include myocardial perfusion and stress MR.

The actions — or inaction — of patients should be considered in programs designed to improve care and patient outcomes, according to a report released by the American College of Cardiology, American Heart Association, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Family Physicians and the American Nurses Association in collaboration with other professional organizations.

LifeWatch AG is signing an agreement with Vital Connect Inc. to utilize their HealthPatch MD as a 1-lead ECG device in its cardiac monitoring business. LifeWatch and Vital Connect are working together to integrate the HealthPatch MD into LifeWatch's analytical mobile application and reporting systems with a view to bringing an integrated solution to market in the first half of 2015.

 

Catalist-listed QT Vascular Ltd. has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.

Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated with Zilver PTX.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now